NSE Symbol: LUPIN | BSE Code: 500257
Lupin was founded on the concept that the products of the company need to make a change in the lives of the people who will consume them. The company is prominent in the pharmaceutical industry especially in countries such as Japan, India and the US. The company relies on cutting-edge research that is supplemented by world-class manufacturing facilities. The company was the second largest pharmaceutical company in India in terms of total revenue in the FY17. The company achieved a consolidated sales of Rs.1,71,198 million in the FY17 with a net profit of Rs.25,575 million.
Desh Bandhu Gupta founded the Lupin Ltd in 1968. He was an Associate Professor at BITS-Pilani in Rajasthan. He served as Chairman in the company until he passed away in 2017. His wife replaced him as Chairman. The company's name is inspired from Lupin flower. The company's vision is to combat life-threatening diseases using drugs. When Lupin manufactured a tuberculosis drug, subsequently it became the world's largest manufacturers of that drug which brought them global recognition.
Mrs. Manju D Gupta is the Chairman of Lupin. Dr. Kamal K Sharma is the Vice Chairman. The CEO of the company is Ms. Vinita Gupta. Mr. Nilesh Gupta is the MD. Mr. Ramesh Swaminathan is the CFO and an Executive Director. Other than these key members, there are six Independent Directors.
Lupin's shares are traded on the BSE and the NSE.
BSE: 500257; NSE: LUPINEQ; ISIN code: INE326A01037; Sector: Pharmaceuticals and healthcare; Industry: Pharmaceuticals
Lupin also listed on other indices like Nifty 50, MCX-SX 40 Index, S&P BSE 100, et cetera.
It also forms a part of the Bangalore Stock Exchange Limited, Cochin Stock Exchange Limited, and so on.
As of March 2018, Lupin has a market capitalization of about Rs.33,000 crore.
According to the fiscal year ending 2017â€“2018, the total income of Lupin was Rs.25,552.3 million. In the previous financial year, the total revenue of the company in the third quarter was, Rs.33,848.4 million.
The total expenses of the company dropped from Rs.21,445.1 million in the second quarter of FY18 to Rs.21,390.1 million in the third quarter of the same financial year.
The total expenditure of the company in the third quarter of the previous financial year was, Rs.21,621.9 million.
The profit before tax for the company in the third quarter of the FY18 was Rs.4,162.2 million which was a dip from the benefit before tax for the previous quarter which was Rs.5,098.2 million.
Lupin has achieved some records in recent years.
According to Bloomberg, in 2017, Lupin was the seventh largest generic pharmaceutical company by market capitalization and the sixth largest company in the generic pharmaceutical category concerning total revenue.
In India, the company was the second largest pharmaceutical company by total revenue in 2017.
In addition to all this, Lupin was the sixth largest generic pharmaceutical company in Japan in 2017.
Also, it is to be noted that Lupin had a consolidated sales amount of Rs.1,71,198 million in FY17 and a net profit of Rs.25,575 million in the same period.
The company has products that address cardiovascular health, diabetes, asthma, gastrointestinal issues, et cetera. These are all health issues that require regular medication.
The company has reported robust sales growth in 20151 2016, and 2017.
While many reasons can be given for investing in Lupin stocks, it would be better to spend after performing personal research, keeping in mind financial freedom and risk appetites.
A lot of research and knowledge is required in stock market investments, and generally, they don't offer any tax benefits. Hence at mymoneykarma, we merely motivate our readers to invest in mutual funds. Investing in mutual funds doesn't require a lot of knowledge, and equity-linked mutual fund schemes also provide tax benefits. In addition to it, since mutual funds contain stocks from multiple companies, they help in building a diversified portfolio.
Note: The contents of this post/blog do not constitute any professional advice on a specific financial matter.